Share-based Payment Arrangement, Expense of Prime Medicine, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Prime Medicine, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Prime Medicine, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $12,747,000, a 87% increase year-over-year.
  • Prime Medicine, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $30,694,000, a 25% increase year-over-year.
  • Prime Medicine, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $26,068,000, a 87% increase from 2023.
  • Prime Medicine, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $13,910,000, a 115% increase from 2022.
  • Prime Medicine, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,459,000, a 270% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Prime Medicine, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $30,694,000 $12,747,000 +$5,920,000 +87% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $24,774,000 $6,325,000 -$1,766,000 -22% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $26,540,000 $5,681,000 +$472,000 +9.1% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $26,068,000 $5,941,000 +$1,512,000 +34% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $24,556,000 $6,827,000 +$2,610,000 +62% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $21,946,000 $8,091,000 +$4,508,000 +126% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $17,438,000 $5,209,000 +$3,528,000 +210% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $13,910,000 $4,429,000 +$1,855,000 +72% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $12,055,000 $4,217,000 +$2,800,000 +198% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $9,255,000 $3,583,000 +$2,238,000 +166% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $7,017,000 $1,681,000 +$558,000 +50% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $6,459,000 $2,574,000 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 $1,417,000 +$1,078,000 +318% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $1,345,000 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $1,123,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $339,000 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3

Prime Medicine, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $26,068,000 +$12,158,000 +87% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $13,910,000 +$7,451,000 +115% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $6,459,000 +$4,713,000 +270% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
2021 $1,746,000 +$1,355,000 +347% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $391,000 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.